Reasearch Awards nomination

Email updates

Keep up to date with the latest news and content from Critical Care and BioMed Central.

Open Access Highly Accessed Research

Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy

Jennifer E Fugate1, Ejaaz A Kalimullah2, Sara E Hocker1, Sarah L Clark3, Eelco FM Wijdicks1 and Alejandro A Rabinstein1*

Author Affiliations

1 Division of Critical Care Neurology, Mayo Clinic, 200 First Street SW, Mayo W8B, Rochester, MN 55905, USA

2 Division of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Mayo W8B, Rochester, MN 55905, USA

3 Department of Pharmacy, Mayo Clinic, 200 First Street SW, Mayo W8B, Rochester, MN 55905, USA

For all author emails, please log on.

Critical Care 2013, 17:R264  doi:10.1186/cc13094

Published: 7 November 2013

Abstract

Introduction

Cefepime, a broad spectrum antibiotic, is commonly prescribed in intensive care units (ICU) and may be an overlooked cause of neurologic symptoms such as encephalopathy, myoclonus, seizures, and coma. We aimed to characterize cefepime neurotoxicity in the ICU.

Methods

We performed a retrospective study of adult ICU patients treated with intravenous cefepime for at least 3 days between January 1, 2009 and December 31, 2011. The primary outcome was the development of cefepime neurotoxicity, with the likelihood of causality ascribed via a modified Delphi method.

Results

This study included 100 patients. The mean age was 65.8 years (± 12.7 years). The median daily average dose of cefepime was 2.5 (IQR 2.0 to 3.5) grams. The median treatment duration was 6 (IQR 4 to 10) days. Renal failure in any form was present in 84 patients. Chronic kidney disease affected 40 patients, and 77 had acute kidney injury. Cefepime neurotoxicity occurred in 15 patients. Of these, seven were considered definite cases, three probable, and five possible. Neurotoxic symptoms included impaired consciousness (n = 13), myoclonus (n = 11), disorientation (n = 6), and nonconvulsive status epilepticus (n = 1). The dose of cefepime was appropriately adjusted for renal clearance in 64 patients (75.3%) without cefepime neurotoxicity and four patients (28.6%) with neurotoxicity (P = 0.001). Chronic kidney disease was present in 30 patients (35.3%) without neurotoxicity and in 10 (66.7%) of those with neurotoxicity (P = 0.04).

Conclusions

Critically ill patients with chronic kidney disease are particularly susceptible to cefepime neurotoxicity. Myoclonus and impaired consciousness are the predominant clinical manifestations. Neurotoxic symptoms occur more often when the cefepime dose is not adjusted for renal function, but can still occur despite those modifications.